GenSight will participate to the Sonoma Eye 2019 congress on March 22-24 2019, at the Fairmont Sonoma Mission Inn, in Sonoma CA.

Barrett Katz, MD, Chief Medical Officer, will present a poster entitled : “Bringing Optogenetics to the Clinic: THE PIONEER STUDY, a Phase 1/2 Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa“.

PIONEER is a Phase 1/2, open-label, non-randomized, dose-escalation study to evaluate the safety and tolerability of GS030, an innovative optogenetic approach combining a gene therapy and a medical device to treat Retinitis Pigmentosa.